These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33504634)

  • 1. Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit.
    Sepúlveda M; Llufriu S; Martínez-Hernández E; Català M; Artola M; Hernando A; Montejo C; Pulido-Valdeolivas I; Martínez-Heras E; Guasp M; Solana E; Llansó L; Escudero D; Aldea M; Prats C; Graus F; Blanco Y; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33504634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
    Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
    Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
    Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
    Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
    Bsteh G; Assar H; Hegen H; Heschl B; Leutmezer F; Di Pauli F; Gradl C; Traxler G; Zulehner G; Rommer P; Wipfler P; Guger M; Enzinger C; Berger T;
    PLoS One; 2021; 16(7):e0255316. PubMed ID: 34314457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
    Arrambide G; Llaneza-González MÁ; Costa-Frossard França L; Meca-Lallana V; Díaz EF; Moreno-Torres I; García-Domínguez JM; Ortega-Suero G; Ayuso-Peralta L; Gómez-Moreno M; Sotoca-Fernández JJ; Caminero-Rodríguez AB; Rodríguez de Antonio LA; Corujo-Suárez M; Otano-Martínez MA; Pérez-Miralles FC; Reyes-Garrido V; Ayuso-Blanco T; Balseiro-Gómez JJ; Muñoz-Pasadas M; Pérez-Molina I; Arnal-García C; Domingo-Santos Á; Guijarro-Castro C; Íñiguez-Martínez C; Téllez Lara N; Castellanos-Pinedo F; Castillo-Triviño T; Cerdán-Santacruz DM; Pérez-Sempere Á; Torres BS; Álvarez de Arcaya A; Costa-Arpín E; Durán-Ferreras E; Fragoso-Martínez M; González-Platas M; Landete Pascual L; Millán-Pascual J; Oreja-Guevara C; Meca-Lallana JE
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34168057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.
    Hadidchi R; Wang SH; Rezko D; Henry S; Coyle PK; Duong TQ
    Mult Scler Relat Disord; 2024 Jun; 86():105613. PubMed ID: 38608516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cancer among Finnish multiple sclerosis patients.
    Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
    Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
    Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
    Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection.
    Maghbooli Z; Hosseinpour H; Fattahi MR; Varzandi T; Hamtaeigashi S; Mohammad-Nabi S; Aghababaei Y; Sahraian MA
    Mult Scler Relat Disord; 2022 Nov; 67():104067. PubMed ID: 35933755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
    Sen S; Karabudak R; Schiavetti I; Demir S; Ozakbas S; Tutuncu M; Petek Balci B; Turan OF; Uzunkopru C; Koseoglu M; Yetkin MF; Gunduz T; Gumus H; Kale Icen N; Carmisciano L; Terzi M; Acar P; Gungor Dogan I; Baba C; Tuncer A; Uygunoglu U; Sormani MP; Efendi H; Siva A;
    Mult Scler Relat Disord; 2021 Jul; 52():102968. PubMed ID: 33940495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.
    Mantero V; Abate L; Balgera R; Basilico P; Salmaggi A; Cordano C
    Mult Scler Relat Disord; 2020 Nov; 46():102453. PubMed ID: 32835900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
    Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
    Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review.
    Barzegar M; Mirmosayyeb O; Gajarzadeh M; Afshari-Safavi A; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34016734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A; Cárdenas-Robledo S; Tagliani P; Arrambide G; Otero-Romero S; Carbonell-Mirabent P; Rodriguez-Barranco M; Rodríguez-Acevedo B; Restrepo Vera JL; Resina-Salles M; Midaglia L; Vidal-Jordana A; Río J; Galan I; Castillo J; Cobo-Calvo Á; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Eur J Neurol; 2021 Oct; 28(10):3384-3395. PubMed ID: 33340215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East.
    Alroughani R; Inshasi J; Al-Hashel J; Alkhaboury J; Alsalti A; Al Suwaidi R; Hassino LH; Farouk Ahmed S
    J Clin Neurosci; 2022 May; 99():311-316. PubMed ID: 35339046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 clinical outcomes and DMT of MS patients and population-based controls.
    Longinetti E; Bower H; McKay KA; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergård J; Olsson T; Piehl F; Frisell T
    Ann Clin Transl Neurol; 2022 Sep; 9(9):1449-1458. PubMed ID: 35993445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine.
    Tejada Cifuentes F; Lloret Callejo Á; Tirado Peláez MJ; Rubio Pulido O; Ruiz-Morote Aragón M; Fernández Urrusuno R; Muñoz Carreras MI; Méndez Esteban MI; Maestre Sánchez V; García Bonilla A; Paredero Dominguez JM; Arroyo Pineda V; Marco Tejón E; Romero Candel G; Fernández Marchante AI; Marco Del Rio J; Ortiz Martín T; López Sánchez P
    Med Clin (Barc); 2021 Feb; 156(4):166-171. PubMed ID: 33308853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of Gender Differences in the Diagnosis and Management of Coronavirus Disease 2019 Patients: An Analysis of Electronic Health Records Using Natural Language Processing and Machine Learning.
    Ancochea J; Izquierdo JL; Soriano JB
    J Womens Health (Larchmt); 2021 Mar; 30(3):393-404. PubMed ID: 33416429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.